Axovant Gene Therapies (NASDAQ:AXGT) issued its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $1.25, Fidelity Earnings reports.

NASDAQ:AXGT traded up $0.06 during mid-day trading on Wednesday, hitting $4.00. The stock had a trading volume of 14,202 shares, compared to its average volume of 293,674. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $39.52. The company has a debt-to-equity ratio of 1.24, a quick ratio of 2.02 and a current ratio of 2.02. The company has a market capitalization of $89.75 million, a P/E ratio of -0.24 and a beta of 1.39.

An institutional investor recently bought a new position in Axovant Gene Therapies stock. Morgan Stanley acquired a new position in shares of Axovant Gene Therapies Ltd (NASDAQ:AXGT) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 219,097 shares of the company’s stock, valued at approximately $291,000. Morgan Stanley owned 0.96% of Axovant Gene Therapies at the end of the most recent reporting period.

Several equities analysts have recently weighed in on AXGT shares. Cowen reaffirmed a “hold” rating on shares of Axovant Gene Therapies in a research note on Wednesday, May 1st. JMP Securities raised their target price on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, June 6th. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a “hold” rating to a “strong-buy” rating and set a $9.00 target price on the stock in a report on Tuesday, May 14th. ValuEngine upgraded shares of Axovant Gene Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $56.00 price target on shares of Axovant Gene Therapies in a research report on Tuesday, March 12th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $36.20.

WARNING: “Axovant Gene Therapies (NASDAQ:AXGT) Posts Quarterly Earnings Results, Beats Estimates By $1.25 EPS” was published by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.mareainformativa.com/news/2019/06/12/axovant-gene-therapies-nasdaqaxgt-posts-quarterly-earnings-results-beats-estimates-by-1-25-eps.html.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

See Also: Asset Allocation Models, Which is Right For You?

Earnings History for Axovant Gene Therapies (NASDAQ:AXGT)

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.